AdipoGen Life Sciences

IL-38 (aa 3-152) (mouse) (rec.) (FLAG)

CHF 350.00

In stock

AG-40B-0101-C01010 µgCHF 350.00

AG-40B-0101-30103 x 10 µgCHF 700.00

For Long-lasting Alternative see AG-40B-0227

More Information
Product Details
Synonyms	Interleukin-38; Interleukin-1 Family Member 10; IL-1F10
Product Type	Protein
Properties
Source/Host	E. coli
Sequence	Mouse IL-38 [IL-1F10] (aa 3-152) is fused at the C-terminus to a FLAG^®-tag.
Crossreactivity	Mouse
MW	~20kDa
Purity	≥95% (SDS-PAGE)
Endotoxin Content	<0.01EU/μg purified protein (LAL test; Lonza).
Concentration	0.1mg/ml after reconstitution.
Reconstitution	Reconstitute with 100μl sterile water.
Formulation	Lyophilized. Contains PBS + 0.5% Trehalose + 0.02% CHAPS.
Other Product Data	Uni-Prot link Q8R459: Interleukin-38
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability	Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

IL-38 (IL-1F10) mRNA is expressed in heart, placenta, fetal liver, spleen, thymus and tonsil. The expression in a variety of immune tissues and similarity to IL-1Ra suggest a role of IL-1F10 in the inflammatory response. It has been reported that removal of the N-terminus domain of the interleukins of the IL-1F family such as IL-1F5 / 6 / 8 or 9 (also called IL-36Ra, IL-36α, IL-36β or IL-36γ) is important to increase their biological activity. Recently it has been shown that IL-38 is N-terminally processed and secreted by apoptotic cells. Released processed IL-38 (20-152) binds to the receptor Interleukin-1 receptor accessory protein-like 1 (IL1RAPL1; TIGIRR-2) at the surface of macrophages. Processed IL-38-activated IL1RAPL1 reduces the production of IL-6 leading to inflammation attenuation.

Product References

In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice: M. Chu, et al.; Immunobiology 222, 483 (2017)
The effect of interleukin 38 on angiogenesis in a model of oxygen-induced retinopathy: J. Zhang, et al.; Sci. Rep. 7, 2756 (2017)
The enigmatic role of IL-38 in inflammatory diseases: T. Garraud, et al.; Cytokine Growth Factor Rev. 39, 26 (2018)
Interleukin 38 protects against lethal sepsis: F. Xu, et al.; J. Infect. Dis. 218, 1175 (2018)
The Effect of Interleukin 38 on Inflammation-induced Corneal Neovascularization: J. Zhu, et al.; Curr. Mol. Med. 19, 589 (2018)
Interleukin‐38 alleviates cardiac remodelling after myocardial infarction: Y. Wei, et al.; J. Cell. Mol. Med. 24, 371 (2020)
IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis: W.D. Xu, et al.; J. Cell Mol. Med. 24,12379 (2020)
IL-38 Alleviates Inflammation in Sepsis in Mice by Inhibiting Macrophage Apoptosis and Activation of the NLRP3 Inflammasome: Y. Ge, et al.; Mediat. Inflamm. 6370911 (2021)
Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity: H. Li, et al.; Invest. Ophthalmol. Vis. Sci. 62, (2021)
Multifaceted roles of IL-38 in inflammation and cancer: A. Diaz-Barreiro, et al.; Cytokine 151, 155808 (2022)
IL-38, a potential therapeutic agent for lupus, inhibits lupus progression: WD. Xu, et al.; Inflamm. Res. 71, 963 (2022)
Regulatory effect of IL-38 on NF-κB pathway in systemic lupus erythematosus: J. Zhang, et al.; Immunobiol. 228, 152322 (2023)

Call	+41 61 926 6040
Fax	+41 61 926 6049